Business
Cosmos Health Releases 2024-2027 Updated Guidance; Projects Revenue of $155.8M and Adjusted EBITDA of $29.4M Annually by 2027, Driven by Strategic Focus on High-Margin Segments
CHICAGO, IL / ACCESSWIRE / September 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated
About this update from Cosmos Health Inc.
[{"type":"text","content":"CHICAGO, IL / ACCESSWIRE / September 18, 2024 / Cosmos Health Inc. (\"Cosmos Health\" or the \"Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today its updated guidance for the 2024-2027 period.Key highlights of the guidance include:Revenue is projected to increase by 163%, from $59.35 million in 2024 to $155.80 million in 2027.Gross profit is expected to rise by 653%, from $6.25 million in 2024 to $47.06 million in 2027.Gross profit margin is anticipated to expand by 1,970 basis points, from 10.50% in 2024 to 30.20% in 2027.Net income is projected to increase by 402%, reaching $20.44 million in 2027, from a loss of $6.76 million in 2024.Adjusted EBITDA is expected to grow to $29.40 million in 2027, from a loss of $1.21 million in 2024.The above achievements are expected to stem from a combination of strategic factors, including a focus on higher-margin business segments, operational synergies, and improved cost efficiency. Specifically, the Company will prioritize the following initiatives, among others:Expansion of Sky Premium Life's geographical footprint and product portfolio, with the introduction of new formulas, therapeutic areas, and customized offerings, supported by strategic partnerships with exclusive distributors and digital channels.The global launch of C-sept and C-scrub, both with significant market potential and limited competition. Production is being scaled up, with additional products in development.Expansion of generic pharmaceuticals across the EU and other international markets, with a focus on advanced generics and innovative OTC products.Optimization of Contract Manufacturing Organization (CMO) operations, with a focus on high-demand medicines and competitive pricing.Progress toward World Medical Organization (WMO) patent approval and completion of clinical trials for the CCX obesity pill by 2025, with commercialization expected in 2026.Driving organic growth and integrating the pharmacy distribution network for enhanced efficiency and scalability.Corporate reorganization focused on cost-cutting initiatives and optimizing asset and resource utilization through the integration o...